Digital technology company Valo Health has an artificial intelligence platform for drug research and a series of compounds produced by the software, but it no longer has the tools to bring them to the public market. Valo and Khosla Ventures Acquisition Co. termination The merger agreement will combine self-described “digital native” therapeutic biotechnology with a special purpose acquisition company (SPAC).
The two companies described the termination of the agreement as a mutual decision. The reason they put forward in their announcement late Monday was “current market conditions, especially in the biotechnology sector.” No additional details were provided. The termination occurred before the scheduled vote on Tuesday by Khosla shareholders on whether to approve the merger transaction.According to the terms Merger agreement, The transaction can be terminated by the written consent of both parties, and neither party assumes any responsibility for the other party.
Valo, headquartered in Boston, was launched last fall and has received more than $100 million in funding since its establishment, and was initially funded by the venture capital firm Flagship Pioneering in 2019. The company’s drug discovery technology, called Opal, aims to improve old drug research by using artificial intelligence to run simulations and optimize a series of molecular characteristics (such as its anti-disease activity, how the body handles it, and reduce the toxic effects of compounds). .
Opal’s AI algorithm is also applied to patient data, and analyzing these data can identify patterns of drug response, which in turn helps identify patient subgroups for experimental treatment. This process becomes a feedback loop. The insights gathered from the experiment are fed back to Opal, where machine learning technology learns and shapes future experiments. When the merger was announced in June, Valo claims that Opal has built more than 30,000 prediction models and made more than 2 billion predictionsThe company believes that, compared with traditional drug development, Opal is likely to advance drug candidates in half the time, half the cost, and fewer drug failures.
Valo technology has produced drug candidates. The company reported a pipeline of 17 projects, covering cardiovascular/metabolic/kidney diseases, cancer, and neurodegenerative diseases. The acute kidney injury drugs OPL-0301 and OPL-0401, which are used to treat diabetic complications, are Valo’s most advanced projects, and they are both preparing to start the second phase of testing.
In the termination announcement, Valo’s founder and CEO David Berry stated that the company is close to launching its Phase 2 trial later this year, and will launch the second phase in the first half of 2022. test. These and other projects in the Valo pipeline will be supported by cash from the merger of SPACs. Khosla brought approximately US$333 million to the merger. The transaction also received additional private financing, which is expected to raise US$168.5 million. The financing increased by another US$32.3 million in July and another US$1.1 million last week. With the termination of the merger transaction, the investment will not occur.
In the termination announcement, Samir Kaul, the founding partner and managing director of Khosla Ventures, stated that SPAC is now looking for other merger opportunities, but not necessarily in the field of biotechnology.
“Valo Health is a strong company, and we hope that they will continue to succeed because they are moving towards a very solid plan,” he said. “We will continue to look for other high-impact targets in various industries to maximize shareholder value.”
Valo will need cash on hand to fund its clinical trial program. When the merger agreement was first announced in the summer, the company stated that its cash holdings were approximately $250 million. More cash may come from partnerships. In addition to supporting internal channels, Valo also stated that Opal can be the basis for transactions with other companies that want to use the technology to gain insights into their drug research.
Photo: Kuzma, Getty Images
